GlassScriptPhysician profile
Nicholas Anthony Pantano
NPI 1417454463
$7,759.65
in general payments reported to CMS, 2019-2025
45 companies · $2,234 in 2025
The $2,234 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $1,956 · 2023: $1,822 · 2024: $1,414 · 2025: $2,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,391 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,390.61 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $829.17 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $825.14 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $712.25 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $662.37 | 2021-2025 | |
| Astellas Pharma US INC | $498.01 | 2021-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.83 | 2022-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Pfizer INC. | $413.88 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.17 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $304.04 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Exact Sciences Corporation | $293.24 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alk-Abello, INC | $210.86 | 2025 | Grastek, Ragwitek, Odactra |
| Otsuka America Pharmaceutical, INC. | $203.75 | 2022-2025 | Rexulti |
| Daiichi Sankyo INC. | $188.39 | 2022-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $157.38 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Axsome Therapeutics, INC. | $140.08 | 2023-2025 | Auvelity |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Pantano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.